Alternative agents in asthma
Identifieur interne : 002418 ( Main/Exploration ); précédent : 002417; suivant : 002419Alternative agents in asthma
Auteurs : Anthony J. Frew ; Martin J. PlummeridgeSource :
- The Journal of Allergy and Clinical Immunology [ 0091-6749 ] ; 2001.
English descriptors
- Teeft :
- Adverse effects, Airway, Airway eosinophilia, Airway hyperresponsiveness, Airway inflammation, Allergen, Allergy, Allergy clin immunol, Allergy clin immunol july, Allergy clin immunol volume, Alternative agents, Animal models, Asthma, Asthma control, Asthma therapy, Asthmatic, Asthmatic subjects, Beclomethasone, Bronchial hyperresponsiveness, Chemokines, Clin, Corticosteroid, Crit, Cyclosporin, Cytokine, Dos, Eosinophil, Eosinophilia, Frew, Hyperresponsiveness, Immunoglobulin, Immunol, Inflammation, Inhaled, Inhaled corticosteroids, Inhibitory effects, Intravenous immunoglobulin, Late asthmatic reaction, Leukotriene, Leukotriene receptor antagonists, Lung function, Mast cells, Methotrexate, Monoclonal antibody, Mouse model, Ocss, Oral steroids, Placebo, Placebo group, Plummeridge, Receptor, Respir, Respir crit care, Rheumatoid arthritis, Severe asthma, Side effects, Steroid, Steroiddependent asthma, Substantial reduction, Troleandomycin.
Abstract
Abstract: Glucocorticosteroids are the backbone of asthma therapy and are administered mainly by the inhaled route. Patients with “difficult” asthma are not a single homogeneous group. Some are stable on high-dose steroid therapy but experience unacceptable side effects; others remain unstable despite receiving high doses of inhaled or oral steroids. Several different steroid-sparing and alternative agents have been tried, with varying degrees of success. Some success has been achieved with conventional immunosuppressants such as methotrexate, gold, and cyclosporin A, but these agents can be justified only in a limited range of cases. Leukotriene receptor antagonists have proved a useful addition to asthma therapy and have been shown to have a modest steroid-sparing effect. Although the existing range of alternative agents has not proved to be particularly effective, several new therapeutic agents have been developed to target specific components of the inflammatory process in asthma. These include IgE antibodies, cytokines, chemokines, and vascular adhesion molecules. Future developments might include better forms of immunotherapy and strategies targeting the remodeling of structural elements of the airways. (J Allergy Clin Immunol 2001;108:3-10.)
Url:
DOI: 10.1067/mai.2001.115758
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000256
- to stream Istex, to step Curation: 000256
- to stream Istex, to step Checkpoint: 001244
- to stream Main, to step Merge: 002443
- to stream Main, to step Curation: 002418
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Alternative agents in asthma</title><author><name sortKey="Frew, Anthony J" sort="Frew, Anthony J" uniqKey="Frew A" first="Anthony J." last="Frew">Anthony J. Frew</name></author><author><name sortKey="Plummeridge, Martin J" sort="Plummeridge, Martin J" uniqKey="Plummeridge M" first="Martin J." last="Plummeridge">Martin J. Plummeridge</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8521E2F32D647F1629932ED8198C7ABEA6AD84AF</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1067/mai.2001.115758</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-GL2XHW6G-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000256</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000256</idno><idno type="wicri:Area/Istex/Curation">000256</idno><idno type="wicri:Area/Istex/Checkpoint">001244</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001244</idno><idno type="wicri:doubleKey">0091-6749:2001:Frew A:alternative:agents:in</idno><idno type="wicri:Area/Main/Merge">002443</idno><idno type="wicri:Area/Main/Curation">002418</idno><idno type="wicri:Area/Main/Exploration">002418</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Alternative agents in asthma</title><author><name sortKey="Frew, Anthony J" sort="Frew, Anthony J" uniqKey="Frew A" first="Anthony J." last="Frew">Anthony J. Frew</name><affiliation><wicri:noCountry code="subField">Bristol.</wicri:noCountry></affiliation></author><author><name sortKey="Plummeridge, Martin J" sort="Plummeridge, Martin J" uniqKey="Plummeridge M" first="Martin J." last="Plummeridge">Martin J. Plummeridge</name><affiliation><wicri:noCountry code="subField">Bristol.</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Allergy and Clinical Immunology</title><title level="j" type="abbrev">YMAI</title><idno type="ISSN">0091-6749</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">108</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="3">3</biblScope><biblScope unit="page" to="10">10</biblScope></imprint><idno type="ISSN">0091-6749</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0091-6749</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse effects</term><term>Airway</term><term>Airway eosinophilia</term><term>Airway hyperresponsiveness</term><term>Airway inflammation</term><term>Allergen</term><term>Allergy</term><term>Allergy clin immunol</term><term>Allergy clin immunol july</term><term>Allergy clin immunol volume</term><term>Alternative agents</term><term>Animal models</term><term>Asthma</term><term>Asthma control</term><term>Asthma therapy</term><term>Asthmatic</term><term>Asthmatic subjects</term><term>Beclomethasone</term><term>Bronchial hyperresponsiveness</term><term>Chemokines</term><term>Clin</term><term>Corticosteroid</term><term>Crit</term><term>Cyclosporin</term><term>Cytokine</term><term>Dos</term><term>Eosinophil</term><term>Eosinophilia</term><term>Frew</term><term>Hyperresponsiveness</term><term>Immunoglobulin</term><term>Immunol</term><term>Inflammation</term><term>Inhaled</term><term>Inhaled corticosteroids</term><term>Inhibitory effects</term><term>Intravenous immunoglobulin</term><term>Late asthmatic reaction</term><term>Leukotriene</term><term>Leukotriene receptor antagonists</term><term>Lung function</term><term>Mast cells</term><term>Methotrexate</term><term>Monoclonal antibody</term><term>Mouse model</term><term>Ocss</term><term>Oral steroids</term><term>Placebo</term><term>Placebo group</term><term>Plummeridge</term><term>Receptor</term><term>Respir</term><term>Respir crit care</term><term>Rheumatoid arthritis</term><term>Severe asthma</term><term>Side effects</term><term>Steroid</term><term>Steroiddependent asthma</term><term>Substantial reduction</term><term>Troleandomycin</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Glucocorticosteroids are the backbone of asthma therapy and are administered mainly by the inhaled route. Patients with “difficult” asthma are not a single homogeneous group. Some are stable on high-dose steroid therapy but experience unacceptable side effects; others remain unstable despite receiving high doses of inhaled or oral steroids. Several different steroid-sparing and alternative agents have been tried, with varying degrees of success. Some success has been achieved with conventional immunosuppressants such as methotrexate, gold, and cyclosporin A, but these agents can be justified only in a limited range of cases. Leukotriene receptor antagonists have proved a useful addition to asthma therapy and have been shown to have a modest steroid-sparing effect. Although the existing range of alternative agents has not proved to be particularly effective, several new therapeutic agents have been developed to target specific components of the inflammatory process in asthma. These include IgE antibodies, cytokines, chemokines, and vascular adhesion molecules. Future developments might include better forms of immunotherapy and strategies targeting the remodeling of structural elements of the airways. (J Allergy Clin Immunol 2001;108:3-10.)</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Frew, Anthony J" sort="Frew, Anthony J" uniqKey="Frew A" first="Anthony J." last="Frew">Anthony J. Frew</name><name sortKey="Plummeridge, Martin J" sort="Plummeridge, Martin J" uniqKey="Plummeridge M" first="Martin J." last="Plummeridge">Martin J. Plummeridge</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002418 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002418 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8521E2F32D647F1629932ED8198C7ABEA6AD84AF
|texte= Alternative agents in asthma
}}
| This area was generated with Dilib version V0.6.33. |  |